On January 11th, Novo Nordisk announced that the world’s first oral glucagon like peptide-1 receptor agonist (GLP-1 RA), Novohexidine (semaglutide tablets), has been fully launched in China. With convenient oral administration, Novosim helps patients benefit from GLP-1RA drugs earlier, helps them achieve high quality blood glucose standards and comprehensive metabolic management, and brings an innovative category for clinical treatment of type 2 diabetes in China. (Beijing Youth Daily)
Scan code to share